Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products globally. Its primary customer base includes healthcare providers, hospitals, and patients across various regions including Japan, the United States, and Europe. Revenue is generated from the sale of pharmaceutical products in areas such as gastroenterology (approximately 25%), rare diseases (20%), plasma-derived therapies (15%), oncology (20%), and neuroscience (20%). Factors supporting its endurance include a diverse product portfolio and established global presence, while challenges may arise from regulatory hurdles and competition in the pharmaceutical industry.
—
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products globally. Its primary customer base includes healthcare providers, hospitals, and patients across various regions including Japan, the United States, and Europe. Revenue is generated from the sale of pharmaceutical products in areas such as gastroenterology (approximately 25%), rare diseases (20%), plasma-derived therapies (15%), oncology (20%), and neuroscience (20%). Factors supporting its endurance include a diverse product portfolio and established global presence, while challenges may arise from regulatory hurdles and competition in the pharmaceutical industry.
—
Daily adjusted close
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products globally. Its primary customer base includes healthcare providers, hospitals, and patients across various regions including Japan, the United States, and Europe. Revenue is generated from the sale of pharmaceutical products in areas such as gastroenterology (approximately 25%), rare diseases (20%), plasma-derived therapies (15%), oncology (20%), and neuroscience (20%). Factors supporting its endurance include a diverse product portfolio and established global presence, while challenges may arise from regulatory hurdles and competition in the pharmaceutical industry.